Core Viewpoint - WuXi Biologics (02269) has seen a significant stock price increase, with a rise of over 6%, currently trading at HKD 43.72, with a transaction volume of HKD 878 million [1] Financial Performance - WuXi Biologics has released a performance forecast, expecting a revenue growth of approximately 16.7% to RMB 21.79 billion for 2025 [1] - The company's net profit attributable to shareholders is projected to increase by 46.3% to RMB 4.908 billion [1] - Adjusted profit is anticipated to grow by 22.0% to RMB 6.586 billion [1] - Gross margin is expected to improve to 46.0%, an increase of about 5 percentage points year-on-year [1] Analyst Insights - Citi has published a report indicating that WuXi Biologics has issued an earnings upgrade for the second half of 2025, with revenue expected to grow by 17% year-on-year, aligning with market expectations [1] - Adjusted net profit is forecasted to increase by 31% to RMB 3.7 billion, significantly exceeding market expectations [1] - The gross margin is projected to rise by 6.2 percentage points to 48.8%, which is highlighted as a key positive surprise in the earnings upgrade and a major driver of better-than-expected profitability [1] - WuXi Biologics remains a preferred stock in the Chinese CRO and CDMO industry according to the report [1]

药明生物(02269)再涨超6%，截至发稿，涨5.6%，报43.72港元，成交额8.78亿港元。 里昂发布研报称，药明生物就2025年下半年业绩发盈喜，预计收入按年增长17%，大致符合预期；经调 整纯利按年增长31%至37亿元，均远胜市场预期；毛利率按年增6.2个百分点至48.8%，为此次盈喜中的 核心利好惊喜，亦是盈利表现胜预期的主要驱动力。该行表示，在中国CRO和CDMO行业中，药明生 物仍是首选股之一， 消息面上，药明生物近日发布业绩预告，预计2025年收益将增长约16.7%至217.9亿元人民币；归母净利 润将同比增长46.3%至49.08亿元；经调整利润将同比增长22.0%至65.86亿元；毛利率将提升至46.0%， 同比增加约5个百分点。 ...